Bristol-Myers wins FDA okay for Opdivo as treatment for small-cell lung cancer [MarketWatch]
Bristol-Myers Squibb Company (BMY)
Last bristol-myers squibb company earnings: 2/6 07:05 am
Check Earnings Report
US:NYSE Investor Relations:
bms.com/investors.html
Company Research
Source: MarketWatch
Bristol-Myers wins FDA approval for Opdivo as treatment for small cell lung cancer Bristol-Myers Squibb Co. BMY, +1.41% said Friday the U.S. Food and Drug Administration has approved Opdivo as a treatment for certain patients with previously treated small cell lung cancer. The company said the approval makes Opdivo the first and only Immuno-Oncology treatment option for patients with metastatic small cell lung cancer whose cancer has progressed after platinum-based chemotherapy and at least one other line of therapy. The decision was based on overall response rate and duration of response and continued approval may be contingent on verification of clinical benefit in further confirmatory trials. Small cell lung cancer is one of two main types of lung cancer and accounts for 10% to 15% of all lung cancers. It is an aggressive form of the disease and is often only detected when it is at an advanced stage. Bristol-Myers shares rose 0.6% in premarket trade Friday, but are down 0.3% in
Show less
Read more
Impact Snapshot
Event Time:
BMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMY alerts
High impacting Bristol-Myers Squibb Company news events
Weekly update
A roundup of the hottest topics
BMY
News
- FDA requires labeling changes to CAR-T cell therapies to reflect cancer risk [Seeking Alpha]Seeking Alpha
- Earnings Preview: Bristol Myers Squibb (BMY) Q1 Earnings Expected to Decline [Yahoo! Finance]Yahoo! Finance
- Bristol-Myers Squibb (NYSE: BMY) had its price target raised by analysts at Wells Fargo & Company from $51.00 to $52.00. They now have an "equal weight" rating on the stock.MarketBeat
- Pathios Therapeutics Raises $25M in First Close of Series B Financing to Advance First-in-Class Immunotherapy Approach into Clinic [Yahoo! Finance]Yahoo! Finance
- Bristol-Myers Squibb: Market Pessimism Won't Last Forever [Seeking Alpha]Seeking Alpha
BMY
Earnings
- 2/2/24 - Beat
BMY
Sec Filings
- 4/2/24 - Form 4
- 4/2/24 - Form 4
- 4/2/24 - Form 4
- BMY's page on the SEC website